Aurelia Bioscience (Charnwood Discovery) specializes in a comprehensive range of drug discovery technologies aimed at enhancing the efficiency and success of complex drug development projects. Their integrated drug discovery services encompass various disciplines, including bioscience, ADME/DMPK (Absorption, Distribution, Metabolism, Excretion, and Toxicology), medicinal chemistry, and computer-aided drug design. The company employs advanced techniques such as Surface Plasmon Resonance (SPR) for analyzing binding kinetics, fluorescence-based melt curve analysis for assessing protein stability, and quantitative polymerase chain reaction (qPCR) for gene expression studies. These technologies enable the team to tailor their approach to meet the specific needs of each project, facilitating effective collaboration and communication among scientists.

In addition to these foundational techniques, Aurelia Bioscience utilizes innovative tools like Simple Western for protein analysis, IncuCyte for real-time cellular imaging, and flow cytometry for multiplexed cytokine assays. Their capabilities extend to high-throughput screening and assay development, allowing for the identification and optimization of lead compounds. The integration of computational chemistry further enhances their drug discovery process, enabling the team to rationalize structure-activity relationships and guide compound design. This multifaceted approach underscores Aurelia Bioscience's commitment to delivering high-quality drug discovery solutions that are responsive to the unique challenges of their clients.

United Kingdom

Charnwood Discovery is a life sciences company that specializes in research and development services for the biotechnology and pharmaceutical industries.

Aurelia Bioscience(Charnwood Discovery)

Company Details